How Will the Market React to Gilead Sciences, Inc. (GILD) Stock Getting a Neutral Rating

Gilead Sciences, Inc. (GILD) stock is up 0.50% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Gilead Sciences, Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on GILD!

See Full GILD Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GILD Stock Today?

Gilead Sciences, Inc. (GILD) stock is trading at $71.69 as of 1:01 PM on Thursday, Sep 23, a rise of $0.31, or 0.43% from the previous closing price of $71.38. The stock has traded between $71.30 and $72.11 so far today. Volume today is light. So far 2,257,117 shares have traded compared to average volume of 6,604,041 shares. To screen for more stocks like Gilead Sciences, Inc. click here.

More About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Click Here to get the full Stock Report for Gilead Sciences, Inc. stock.